Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 31, 2018
Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHAD
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
January 31, 2018
Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update
ARCHAMPS, France--(BUSINESS WIRE)--Regulatory News: Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today reported cash, ...
January 31, 2018
Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD)
LIVONIA, Mich., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
January 31, 2018
Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
EMERYVILLE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
January 31, 2018
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
January 30, 2018
Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
January 30, 2018
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
VANCOUVER, Jan. 29, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for ...
January 30, 2018
CymaBay Announces Pricing of Public Offering of Common Stock
NEWARK, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
January 30, 2018
BioDelivery Sciences Announces Launch and Availability of BELBUCA® in Canada
RALEIGH, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) --BioDelivery Sciences International, Inc. (BDSI) and Purdue Pharma (Canada) announced today that BELBUCA® (buprenorphine) buccal film is now ...
January 29, 2018
ABIVAX Appoints Carol L. Brosgart, M.D. to its Board of Directors
PARIS, Jan. 29, 2018, 8 a.m. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure ...
January 29, 2018
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
LAVAL, QC, Jan. 29, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") announces today the outcome of a successful clinical development Type C meeting with the US ...
January 29, 2018
Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the ...
January 29, 2018
Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (ARDM) (the “Company”) today announces that it received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding ...
January 29, 2018
Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
MORRISTOWN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that it has entered into a ...
January 29, 2018
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
January 29, 2018
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
PRINCETON , N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the ...
January 29, 2018
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study ...
January 26, 2018
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
LAVAL, QC , Jan. 25, 2018 /CNW/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic") announced  that it will host a Key Opinion Leader (KOL) meeting on ...
January 26, 2018
Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs ...
January 26, 2018
ESSA Announces Management Team Change
HOUSTON and VANCOUVER , Jan. 25, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that  Frank Perabo, ...
Page 79 of 128